Clinical Trial Update: Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of docetaxel, trabectedin, and G-CSF or pegfilgrastim in patients with recurrent or persistent ovarian epithelial cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Filgrastim (filgrastim)
• Pegfilgrastim (pegfilgrastim)
• Trabectedin (trabectedin)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-06-26